alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### National Science Foundation

In accordance with the Federal Advisory Committee Act (Pub. L., 92-463, as amended), the National Science Foundation announces the following meeting:

*Name:*                         Biological Sciences Advisory Committee (#1110).                    

*Date and Time:*                         March 29, 2011; 8:30 a.m. to 5 p.m.                    

March 30, 2011; 8:30 a.m. to 5 p.m.

*Place:*                         National Science Foundation, 1401 Wilson Blvd., Arlington, VA 22230.                    

*Type of Meeting:*                         Open.                    

*Contact Person:*                         Chuck Liarakos, National Science Foundation, Room 605, 4201 Wilson Boulevard, Arlington, VA 22230. Tel No.: (703) 292-8400.                    

*Purpose of Meeting:*                         The Advisory Committee for BIO provides advice, recommendations, and oversight concerning major program emphases, directions, and goals for the research-related activities of the divisions that make up BIO.                    

*Agenda:*                         Items on the agenda include the NSF and BIO FY 2012 budget request, the 2010 America Competes Act, and a progress report on BIO's ongoing experiments in innovation. In addition, the BIO AC will discuss “information exchange environments” and STEM education, workforce and careers in science.                    

Dated: March 4, 2011.

Susanne Bolton,

Committee Management Officer.

[FR Doc. 2011-5364 Filed 3-8-11; 8:45 am]

BILLING CODE 7555-01-P
**Exhibit**
**      32**

**CERTIFICATION      PURSUANT**

**TO      18 U.S.C. SECTION 1350,**

**AS      ADOPTED PURSUANT TO**

**SECTION      906 OF THE SARBANES-OXLEY ACT OF 2002**

| Date:                November 9, 2006 |  **/s/                Paul J. Maddon, M.D., Ph.D.**                                                                         |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
|                                  | Paul                J. Maddon, M.D., Ph.D.Chief                Executive Officer                                                 |
|                                  |                                                                                                                             |
|                                  |                                                                                                                             |
|                                  |  **/s/                Robert A. McKinney**                                                                                  |
|                                  | Robert                A. McKinneyChief                Financial Officer(Principal                Finance and Accounting Officer) |
EX-10.47



 Exhibit 10.47 
  





 
 Insertion Order Amendment No. 1 

 

			
	Advertiser/Agency Information
		
	Advertiser/Agency Name:	  	Resolution Media
		
	Address:	  	225 N Michigan Ave, Suite 820, Chicago, IL 60601
		
	Contact Name/Phone Number:	  	***
		
	Email:	  	***
		
	Campaign Name:	  	State Farm – Auto

  

					
	Campaign Summary
		
	Insertion Order subject to this Amendment:	  	Insertion Order dated December 22, 2015 entered into by and between Marchex Sales, LLC. (f/k/a Marchex Sales, Inc.) (“Company”) and the Advertiser or Agency set forth
above.
	  
 Amended Terms:
	  	  
 The Volume field on the Insertion Order is hereby
deleted and replaced with the following:

			
		  	Estimated Call Volume	  	Total Budget
		  	  
 ***
	  	  
 ***


 Amendment 

Advertiser agrees to pay Company for all calls delivered based on the amended terms of the Campaign Summary set forth herein (“Amendment”). This
Amendment incorporates the terms of the Insertion Order referred to herein, except to the limited extent that such terms were expressly modified by the change in Campaign Summary. Other than the specific terms and conditions expressly referenced
above, this Amendment shall not be construed to modify any term or condition of the Insertion Order, which will otherwise remain unchanged and in full force and effect. 

Authorization 
 By delivering this
Amendment, Advertiser or Agency hereby acknowledges and agrees to abide by the terms of the current Insertion Order except as expressly amended hereby, with the full understanding and acceptance of all terms, policies and conditions referenced
thereon. 
 Agreed and accepted this 20th day of January, 2016: 

 

									
	Authorized Representative for Marchex Sales, LLC:	 		 	Authorized Representative for Advertiser/Agency:
					
	By (Signature):	 	 /s/ Brendhan Hight
	 		 	By: (Signature):	 	 /s/ Kate Edelson

					
	Name:	 	 Brendhan Hight
	 		 	Name:	 	 Kate Edelson

					
	Title:	 	 Director
	 		 	Title:	 	 ABPM


 [***] Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.
§ 381.138 Unauthorized use or disposition of approved labeling or devices. ( a ) Labeling and devices approved for use pursuant to § 381.115 shall be used only for the purpose for which approved, and shall not be disposed of from the official establishment for which approved except with written approval of the Administrator. Any unauthorized use or disposition of approved labeling or devices bearing official inspection marks is prohibited and may result in cancellation of the approval.
( b ) Labeling and containers bearing any official inspection marks, with or without the official establishment number, may be transported from one official establishment to any other official establishment, only if such shipments are made with the prior authorization of the inspector in charge at point of origin, who will notify the inspector in charge at destination concerning the date of shipment, quantity, and type of labeling material involved. Approved labeling and containers may be moved without restriction under this part between official establishments operated by the same person if such labeling and containers are approved for use at all such establishments. No such material shall be used at the establishment to which it is shipped unless such use conforms with the requirements of this subpart.
§ 286.102 Application for rehearing. ( a ) *General rule.* Any person aggrieved by any order or regulation or any amendment to a regulation issued under the NGPA and subject to judicial review under section 506(a) or (b) thereof shall file a petition for rehearing within 30 days after the order or regulation is issued by the Commission or February 3, 1979, whichever is later. There has not been an exhaustion of administrative remedies until a petition for rehearing has been filed under this section and the proceeding is complete by the denial of the request, or if rehearing is granted, an order affirming, modifying or revoking the challenged order or regulation is issued.
( b ) *Specifications of error.* The application for rehearing shall state clearly and concisely with respect to the challenged order or regulation: ( 1 ) The provision of the order or the regulation, by section, and where appropriate, by paragraph;
( 2 ) Applicant's interest in the particular provision; and
( 3 ) The facts and legal analysis upon which the request for rehearing is based.
( c ) *Procedural requirements.* Except as otherwise provided in this section, the procedures for rehearing in § 385.713 of this chapter shall apply.
( d ) *Commission action upon the application.* ( 1 ) The Commission may grant the request for rehearing, in whole or in part, by issuing an order specifying the scope of rehearing. If, and to the extent that rehearing is granted, the Commission may request Staff, applicant or any other party to file briefs. In every case where rehearing is granted, the Commission will issue an order affirming, modifying or revoking the challenged order or regulation.
( 2 ) The Commission may modify the original order or regulation without further hearing.
( 3 ) Unless the Commission acts upon the application within 30 days after it is filed, such application shall be considered to have been denied. If the Commission grants rehearing in part, any part of the application outside the scope of the order granting rehearing shall be considered to have been denied.
[44 FR 2383, Jan. 11, 1979, as amended by Order 225, 47 FR 19058, May 3, 1982]
# C_2010179EN.01004602.xml

| 3.7.2010 | EN | Official Journal of the European Union | C 179/46 |
| --- | --- | --- | --- |

3.7.2010

EN

Official Journal of the European Union

C 179/46

---

Action brought on 29 April 2010 — Apotheke DocMorris v OHIM (Representation of a green and white cross)

(Case T-196/10)

(2010/C 179/81)

Language of the case: German

Parties

Applicant: Apotheke DocMorris Holding GmbH (Stuttgart, Germany) (represented by Y. Dick, lawyer)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Form of order sought

| — | Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 23 February 2010 in Case R 470/2009-4; |
| --- | --- |

—

Annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 23 February 2010 in Case R 470/2009-4;

| — | Order the defendant to pay the costs. |
| --- | --- |

—

Order the defendant to pay the costs.

Pleas in law and main arguments

Community trade mark concerned: Figurative mark representing a green and white cross, in respect of goods and services in Classes 3, 5, 8, 9, 10, 11, 16, 21, 25, 29, 30, 32, 35-42 and 44 — Application No 5 930 979.

Decision of the Examiner: Refusal of the application.

Decision of the Board of Appeal: Dismissal of the appeal.

Pleas in law: Infringement of Article 7(1)(b) of Regulation (EC) No 207/2009 (1), as the Board of Appeal’s assessment in relation to establishing distinctiveness was incorrect in a number of respects.

---

(1)  Council Regulation (EC) No 207/2009 of 26 February 2009 on the Community trade mark (OJ 2009 L 78, p. 1).

---
# Budget Narrative Instructions

# Allowable-Nonallowable Costs

# State Tribe Territory Narrative

Check this box to confirm that this is the usual and customary rate for this organization.

Check this box to confirm that these are the usual and customary rates for this organiztion.

# Provider Narrative

Check this box to confirm that this is the usual and customary rate for this organization.

Check this box to confirm that these are the usual and customary rates for this organization.

# Example - State Tribe Territory

Check this box to confirm that this is the usual and customary rate for this organization.

# Example - Provider 

Check this box to confirm that this is the usual and customary rate for this organization.
BEFORE SHE GETS BEHIND 

THE WHEEL...

Make sure she understands the risks of drunk and 

drugged driving.

Let your child know it’s never okay to get behind the wheel of a motor vehicle 

while under the influence of alcohol or other drugs, and that getting in a car with 

someone who has been drinking or using drugs is also very dangerous. For tips on 

how—and when—to begin the conversation, visit 

www.underagedrinking.samhsa.gov

#TalkTheyHearYou PEP20-03-01-059
**For      Immediate Release**

| **Contact:** | Progenics                Pharmaceuticals, Inc.Richard                W. Krawiec, Ph.D.Vice                President, Corporate Affairs(914)                789-2800rkrawiec@progenics.com |
|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**PROGENICS      PHARMACEUTICALS EXPANDS**

**SENIOR      MANAGEMENT TEAM AND BOARD OF DIRECTORS**

***-      Walter M. Capone named Vice President, Commercial Development and Operations      -***

***-      Nicole S. Williams appointed to Board of Directors -***

**Tarrytown,      NY - January 8, 2007**
**-      **

----

**Company      Profile**

**Progenics      Pharmaceuticals, Inc.**

***DISCLOSURE      NOTICE:***
*The      information contained in this document is current as of January 8, 2007. This      press release contains forward-looking statements. Any statements contained      herein that are not statements of historical fact may be forward-looking      statements. When the Company uses the words ‘anticipates,’ ‘plans,’ ‘expects’and similar expressions, it is identifying forward-looking statements. Such      forward-looking statements involve risks and uncertainties which may cause      the      Company’s actual results, performance or achievements to be materially different      from those expressed or implied by forward-looking statements. Such factors      include, among others, the uncertainties associated with product development,      the risk that clinical trials will not commence or proceed as planned, the      risks      and uncertainties associated with dependence upon the actions of our corporate,      academic and other collaborators and of government regulatory agencies, the      risk      that our licenses to intellectual property may be terminated because of our      failure to have satisfied performance milestones, the risk that products that      appear promising in early clinical trials do not demonstrate efficacy in      larger-scale clinical trials, the risk that we may not be able to manufacture      commercial quantities of our products, the uncertainty of future profitability      and other factors set forth more fully in the Company’s Annual Report on Form      10-K for the fiscal year ended December 31, 2005 and other reports filed with      the Securities and Exchange Commission, to which investors are referred for      further information. In particular, the Company cannot assure you that any      of      its programs will result in a commercial product. *

*Progenics      does not have a policy of updating or revising forward-looking statements and      assumes no obligation to update any forward-looking statements contained in      this      document as a result of new information or future events or developments. Thus,      it should not be assumed that the Company’s silence over time means that actual      events are bearing out as expressed or implied in such forward-looking      statements.*
<PAGE>

                                                                      EXHIBIT 32


      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     In connection with the quarterly report on Form 10-Q of Overhill Farms,
Inc. (the "Company") for the quarter ended July 1, 2007 (the "Report"), the
undersigned hereby certify in their capacities as Chief Executive Officer and
Chief Financial Officer of the Company, respectively, pursuant to 18 U.S.C.
section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

     1. the Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

     2. the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

Dated:  August 8, 2007                 By: /s/ James Rudis
                                           ------------------------------------
                                           James Rudis
                                           Chief Executive Officer
                                           (principal executive officer)


Dated:  August 8, 2007                 By: /s/ John L. Steinbrun
                                           ------------------------------------
                                           John L. Steinbrun
                                           Chief Financial Officer
                                           (principal financial officer)


     A signed original of this written statement required by Section 906, or
other document authenticating, acknowledging, or otherwise adopting the
signatures that appear in typed form within the electronic version of this
written statement required by Section 906, has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.
**Exhibit 31.1**

 

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

 

I, Terry S. Parker, certify that: 

 

1. I have reviewed this annual report on Form 10-K of CellStar Corporation; 

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) for the registrant and have: 

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period in which this report is being prepared; 

 

b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

 

c) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, basedon our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): 

 

a) All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and 

 

b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control over financial reporting. 

 

/s/ Terry S.Parker                                    

Terry S. Parker, Chief Executive Officer 

 

Date: February 25, 2004
Exhibit 99.1

      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul G.  Lego,  certify,  pursuant  to 18 U.S.C.  Section  1350,  as  adopted
pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002,  that the Quarterly
Report of Virage,  Inc. on Form 10-Q for the fiscal quarter ended  September 30,
2002 fully  complies  with the  requirements  of  Section  13(a) or 15(d) of the
Securities Exchange Act of 1934 and that information contained in such Quarterly
Report on Form 10-Q  fairly  presents in all  material  respects  the  financial
condition and results of operations of Virage, Inc.


                                         By: /s/ Paul G. Lego
                                             -----------------------------------
                                             Paul G. Lego
                                             President & Chief Executive Officer


I, Scott Gawel, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the  Sarbanes-Oxley  Act of 2002, that the Quarterly Report of
Virage,  Inc. on Form 10-Q for the fiscal quarter ended September 30, 2002 fully
complies  with the  requirements  of  Section  13(a) or 15(d) of the  Securities
Exchange Act of 1934 and that information  contained in such Quarterly Report on
Form 10-Q fairly presents in all material  respects the financial  condition and
results of operations of Virage, Inc.

                                         By: /s/ Scott Gawel
                                             -----------------------------------
                                             Scott Gawel
                                             Vice President, Finance &
                                             Acting Chief Financial Officer

                                      -17-